Education
About Us
Working with TipRanks
Follow Us
Universe Pharmaceuticals Incorporation (UPC)
:UPC
Total Valuation
Universe Pharmaceuticals has a market cap or net worth of $2.06M. The enterprise value is -$37.45M.
Market Cap$2.06M
Enterprise Value-$37.45M
Share Statistics
Universe Pharmaceuticals has 563,338 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding563,338
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Universe Pharmaceuticals’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -16.11%.
Return on Equity (ROE)-0.19
Return on Assets (ROA)-0.13
Return on Invested Capital (ROIC)-16.11%
Return on Capital Employed (ROCE)-0.17
Revenue Per Employee102.33K
Profits Per Employee-38.79K
Employee Count225
Asset Turnover0.34
Inventory Turnover9.76
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio0.02
Price to Fair Value0.02
Price to FCF-0.44
Price to Operating Cash Flow-0.30
PEG Ratio<0.01
Income Statement
In the last 12 months, Universe Pharmaceuticals had revenue of 23.02M and earned -8.73M in profits. Earnings per share was -1.44K.
Revenue23.02M
Gross Profit6.07M
Operating Income-8.02M
Pretax Income-8.12M
Net Income-8.73M
EBITDA-7.36M
Earnings Per Share (EPS)-1.44K
Cash Flow
In the last 12 months, operating cash flow was -4.52M and capital expenditures -392.21K, giving a free cash flow of -4.91M billion.
Operating Cash Flow-4.52M
Free Cash Flow-4.91M
Free Cash Flow per Share-8.71
Dividends & Yields
Universe Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change-99.83%
50-Day Moving Average4.25
200-Day Moving Average41.40
Relative Strength Index (RSI)45.56
Average Volume (3m)29.93K
Important Dates
Universe Pharmaceuticals upcoming earnings date is Aug 4, 2025, Before Open (Confirmed).
Last Earnings DateFeb 4, 2025
Next Earnings DateAug 4, 2025
Ex-Dividend Date―
Financial Position
Universe Pharmaceuticals as a current ratio of 2.54, with Debt / Equity ratio of 14.01%
Current Ratio2.54
Quick Ratio2.46
Debt to Market Cap8.99
Net Debt to EBITDA2.92
Interest Coverage Ratio-28.83
Taxes
In the past 12 months, Universe Pharmaceuticals has paid 606.70K in taxes.
Income Tax606.70K
Effective Tax Rate-0.07
Enterprise Valuation
Universe Pharmaceuticals EV to EBITDA ratio is 2.80, with an EV/FCF ratio of 2.09.
EV to Sales-0.90
EV to EBITDA2.80
EV to Free Cash Flow2.09
EV to Operating Cash Flow2.17
Balance Sheet
Universe Pharmaceuticals has $47.27M in cash and marketable securities with $7.73M in debt, giving a net cash position of -$39.54M billion.
Cash & Marketable Securities$47.27M
Total Debt$7.73M
Net Cash-$39.54M
Net Cash Per Share-$70.19
Tangible Book Value Per Share$7.44K
Margins
Gross margin is 31.06%, with operating margin of -34.83%, and net profit margin of -37.90%.
Gross Margin31.06%
Operating Margin-34.83%
Pretax Margin-35.27%
Net Profit Margin-37.90%
EBITDA Margin-31.95%
EBIT Margin-34.06%
Analyst Forecast
The average price target for Universe Pharmaceuticals is $4.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$4.00
Price Target Upside9.59% Upside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast-27.81%
EPS Growth Forecast―